In IVF/ICSI cycles, the progesterone levels induced by ovarian stimulation are low; therefore the luteal phase is supported by progesterone. The routes of progesterone supplements could be oral, vaginal, rectal or intramuscular. Currently vaginal progesterone is widely used, since the classic oral progesterone seems to result in a low bioavailability and a lower pregnancy rate. Not to mention that the intramuscular progesterone daily injections are painful and may cause abscesses, inflammatory reactions. Meanwhile, vaginal administration of progesterone is associated with vaginal irritation, discharge and bleeding. Therefore, there is a need for an effective, well tolerated, and safe treatment that can improve patient satisfaction and compliance. 

This is a prospective comparative randomized controlled trial investigating 224 patients who are seeking IVF/ICSI fertility treatment at AUBMC Fertility Center at American University of Beirut Medical Center. We aim to demonstrate the superiority of oral dydrogesterone (Duphaston) 10 over micronized vaginal progesterone (Utrogestan) used for luteal supplementation in cryo-warmed embryo transfer cycles

This is a prospective comparative randomized controlled trial investigating 224 patients who are seeking IVF/ICSI fertility treatment at AUBMC Fertility Center at American University of Beirut Medical Center.